108 results about "Induced pluripotent stem cell" patented technology

The invention discloses a fish liver acellular matrix-based microfluidic 3D printing hydrogel for liver regeneration and a preparation method thereof, the fish liver acellular matrix (dECM) and gelatin methacryloyl (GelMA) are combined together, and induced pluripotent stem cell-derived hepatocytes (iPSC-hep) are loaded for liver regeneration. The microfluidic 3D printing hydrogel based on the fish liver acellular matrix has excellent biocompatibility, retains complete endogenous growth factors, retains the biological activity of cells, ensures effective cell encapsulation, and is beneficial to stable functional expression of iPSC-hep. After in-vivo transplantation, the survival rate and the liver function of acute hepatic failure mice are remarkably improved, and regeneration and repair of the liver are promoted.

Provided are chemical inducers of pluripotency (CIP) which include glycogen synthase kinase inhibitors, TGFβ receptor inhibitors, cyclic AMP agonists and S-adenosylhomocysteine hydrolase (SAH) inhibitors or histone acetylators. A method of inducing pluripotency in a partially or completely differentiated cell by using such chemical inducers of pluripotency is also provided. The method includes: (i) contacting a cell with the CIPs for a sufficient period of time to result in reprograming the cell into a pluripotent stem cell having ESC-like characteristics (CiPSC). Isolated chemically induced pluripotent stem cells (CiPSCs) and their progeny, produced by inducing differentiation of the CiPSCs, can be used in a number of applications, including but not limited to cell therapy and tissue engineering.

Disclosed in the present invention are a biomimetic vascularized iPSC-hep spheroid for liver regeneration, and a preparation method therefor. The biomimetic vascularized iPSC-hep spheroid is a microcapsule with a porous hyaluronic acid methacryloyl as a shell and a human-induced pluripotent stem-cell-derived hepatocyte spheroid as an inner phase, and human umbilical vein endothelial cells adhere to the surface of the shell. The biomimetic vascularized iPSC-hep spheroid of the present invention promotes effective communication between hiPSC-heps and HUVECs, and provides barrier protection for an encapsulated hiPSC-hep spheroid so as to avoid attack by the immune system. Compared with dispersed cells, the cell-to-cell interaction in the cell spheroid improves cell-to-cell communication, helps to simulate the physiological heterogeneous structure and cell microenvironment of the liver, and can more effectively repair an acutely failing liver.

According to one embodiment, an initialization agent is for initializing blood cells derived from peripheral blood. The initialization agent includes an initialization factor group for producing iPS cells by initializing a group of blood cells including mononuclear cells derived from peripheral blood, and a group of lipid nanoparticles that encapsulate the initialization factor group. The lipid nanoparticles have a component of at least or more of 40% FFT-10 and FFT-20. FFT-10 and FFT-20 are included in equal amounts.

Provided are a method for inducing differentiation of pluripotent stem cells into CD34+ hematopoietic stem / progenitor cells and a culture medium composition thereof. Provided are a method for inducing differentiation of pluripotent stem cells into CD34+ hematopoietic stem / progenitor cells or NK cells and a culture medium composition thereof. The NK cells obtained using the provided culture method have high purity and good in vitro expansion effect; the yield of iNK cells is high, and a single iPSC can differentiate into approximately 2,000 NK cells; and the obtained iNK cells highly express CD16 (over 70%). As a result, the problem of low CD16 expression in iNK cells in the prior art, which requires genetic modification methods to solve, has been addressed.

Organs-on-chips are microfluidic devices for culturing living cells in micrometer sized chambers in order to model physiological functions of tissues and organs. Engineered patterning and continuous fluid flow in these devices has allowed culturing of intestinal cells bearing physiologically relevant features and sustained exposure to bacteria while maintaining cellular viability, thereby allowing study of inflammatory bowl diseases. However, existing intestinal cells do not possess all physiologically relevant subtypes, do not possess the repertoire of genetic variations, or allow for study of other important cellular actors such as immune cells. Use of iPSC-derived epithelium, including IBD patient-specific cells, allows for superior disease modeling by capturing the multi-faceted nature of the disease.

The present invention relates to a method for producing adipocyte-derived dedifferentiated stem cells by using centrifugation. The method for producing adipose cell-derived dedifferentiated stem cells by using centrifugation, and adipose cell-derived dedifferentiated stem cells using same, according to one embodiment of the present invention, allow a production period to be significantly shorter than that of adipose cell-derived dedifferentiated stem cells produced using a conventional ceiling culture method, and thus can be effectively used in the field of autologous adipose-derived stem cell therapeutic agents.

An object of the present invention is to provide a novel method for inducing the differentiation of pluripotent stem cells into an insulin-positive cell population. The present invention provides a method for producing an insulin-positive cell population, comprising culturing and differentiating a pancreatic progenitor cell population or a cell population at a later stage of differentiation in a medium containing substantially no 2-(3-(6-methylpyridin-2-yl)-1H-pyrazol-4-yl)-1,5-naphthyridine and containing a factor having ALK5-inhibiting activity and CDK8 / 19-inhibiting activity.

A method of assessing the safety of a gene therapy vector comprising: providing a population of genetically modified cells 18 wherein the cells have been transfected with a vector; exposing the genetically edited cells to a carcinogen 20; growing the cells to produce immortal cell lines; and comparing the survival of the test cells with a control 14 to determine if the vector contributes to carcinogenicity. Also claimed is a method of testing the safety of a vector comprising: providing test cells; genetically editing the cells with a vector and exposing cells to a carcinogen or exposing the cells to a carcinogen and modifying the cells with a vector; growing the cells; and comparing the survival of the cells to a control. The cells may be used in immunotherapy. The cells may be CAR-T cells. The cells may be from peripheral blood mononuclear cells or induced pluripotent stem cells (iPSCs). The carcinogen may be ENUA. Also claimed is a method of designing a vector for use in gene therapy by harvesting nucleic acid from the test cells, characterising the modification of the test cells, redesigning the vector, and repeating the method of testing the safety of the vector.

The present disclosure relates to genetically modified cells (e.g., iPSC, IPS-derived immune cells, e.g., NK or T cells, or NK cells or T cells) comprising a disrupted FAS gene, an insertion of a polynucleotide encoding an IL15 / IL15Rα fusion, and an insertion of a polynucleotide encoding a CAR, e.g., an anti-GPR87 CAR. Therapeutic uses of the genetically modified cells to treat cancer (e.g., a lung cancer) are also provided.

Provided are genetically engineered induced pluripotent stem cells (iPSCs) and derivative cells thereof expressing a chimeric antigen receptor (CAR) and methods of using the same. Also provided are compositions, polypeptides, vectors, and methods of manufacturing.

[Summary] [Problems] The main purpose of this invention is to provide a technique for inducing an epidermal keratinocyte that can produce a three-dimensional cultured skin model with a multi-layered horny cell layer, from a pluripotent stem cell. [Solution] The present invention is a method for inducing differentiation from a pluripotent stem cell to an epidermal keratinocyte, using a non-detached cell after being treated with a cell detaching agent in the inducing step from the pluripotent stem cell, wherein when applying the epidermal keratinocyte to a three-dimensional cultured skin model, a three-dimensional cultured skin model in which the horny cell layer is multi-layered is obtained.

Disclosed herein are devices, compositions, methods, and systems for identifying mammalian cells, especially erythrocytes, with enhanced characteristics, such as hemolysis, stress tolerance, oxygen capacity, and energy metabolism. In some embodiments, the devices, compositions, methods, and systems may be useful in identifying a subject for donating erythrocytes, with enhanced stress resistance, with enhanced physical performance such as oxygen consumption, and strenuous or prolonged physical activities, hemorrhage, or resistance to high altitude hypoxia. Subjects may also be identified for donating cells for use in manufacture of next-generation ex vivo farmed RBCs with optimal storage and resuscitation performances. The disclosed devices, compositions, methods and systems are also useful in the bioengineering of red blood cells and red blood cell precursor ex vivo from hematopoietic stem cells or induced pluripotent stem cells, as well as ithe prediction of cancer progression, severity and responses to therapies targeting glycolysis.

The present invention provides: a method for differentiating pluripotent stem cells into mesenchymal stem cells in the presence of a BMP4 signaling agonist; mesenchymal stem cells obtained thereby; and extracellular vesicles obtained from a culture solution of the stem cells. The extracellular vesicles have excellent anti-inflammatory effects, and thus can be used for treating inflammatory diseases. Therefore, there is a high possibility that a composition comprising the extracellular vesicles can be variously used as a pharmaceutical composition for treatment of inflammatory diseases and a cosmetic composition for skin improvement.

The present invention provides a novel method for producing natural killer (NK) cells, which enables production of a large amount of high-quality NK cells easily, inexpensively, and safely in a short period of time from pluripotent stem cells. Specifically, a method for producing NK cells is provided, including(1) a step of forming pluripotent stem cell spheres having an average particle size of not less than 200 μm in a first medium;(2) a step of inducing the pluripotent stem cell spheres formed in step (1) into a cell population including hematopoietic progenitor cells by three-dimensional culture using a second medium; and(3) a step of inducing the cell population including hematopoietic progenitor cells obtained in step (2) into a cell population including NK cells by three-dimensional culture using a third medium,wherein the steps (1) to (3) are performed by a perfusion culture method.

Disclosed are methods for culturing coronavirus particles in early syncytiotrophoblasts (eSTBs). The derived eSTBs are mononucleated or bi-nucleated cells with high ACE2 expression and are not multi-n

The present invention provides improved methods for producing retinal pigmented epithelial (RPE) cells from human embryonic stem cells, human induced pluripotent stem (iPS), human adult stem cells, human hematopoietic stem cells, human fetal stem cells, human mesenchymal stem cells, human postpartum stem cells, human multipotent stem cells, or human embryonic germ cells. The RPE cells derived from embryonic stem cells are molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The RPE cells described herein are useful for treating retinal degenerative conditions including retinal detachment and macular degeneration.

To provide means for evaluating a differentiation state of a cell with higher accuracy.SOLUTION: Provided is a method of inducing the differentiation of a pluripotent stem cell into a cardiomyocyte in a liquid culture medium by first induction treatment of inducing the differentiation of a pluripotent stem cell into a mesodermal cell and second induction treatment of inducing the differentiation of a mesodermal cell into a cardiomyocyte, collecting supernatant of a liquid culture medium including the cell whose differentiation is induced by the second induction treatment, measuring miRNA-3p of miR-1 / 133a cluster in the supernatant, and determining a differentiation state of the cell on the basis of the miRNA-3p measured value.SELECTED DRAWING: Figure 10

To provide a method for producing corneal endothelial substitute cells to which novel functionality has been imparted, particularly a method for producing corneal endothelial substitute cells derived from iPS cells.SOLUTION: A method for producing functionalized corneal endothelial substitute cells is provided, comprising the steps of: introducing a nucleic acid encoding a functional molecule into the genome of a pluripotent stem cell; and inducing the pluripotent stem cell containing the introduced nucleic acid into a corneal endothelial substitute cell.SELECTED DRAWING: None

The present invention relates to the use of a composition comprising the following compounds: activin A, BMP4, CHIR99, EGF, FGF 8, FGF 10, IGF1, LY3, Noggin, retinoic acid and Y27 for carrying out a process of inducing the differentiation of pluripotent stem cells or iPSc into functional thymic epithelial progenitor cells or TEP, preferably in vitro or ex vivo.

The present invention provides microparticles that induce the migration of multipotent stem cells to the anatomical site of the microparticles. Various release profiles are demonstrated that depend upon the relative concentration of alginate in the chemokine-loaded microparticle. Local administration and / or intraarticular injection of the microparticles are useful in conditions such as osteoarthritis. Targeted systemic delivery of the alginate chemokine microparticles to distant anatomical sites subjected to autoimmune disease symptomology can be performed by encapsulation within liposomes having targeting ligands. Consequently, upon the creation of the appropriate chemokine gradient, multipotent stem cells will migrate to the distant anatomical site where the liposomes are attached.

Methods for maintaining aggregate stability and pluripotency of human stem cells are provided using chemically -defined culture media that includes heparin sodium salt and polyethylene glycol. Methods of modulating aggregate size and / or stability using chemically-defined culture media are also provided. The methods can be used with, for example, induced pluripotent stem cells or embryonic stem cells. Culture media and kits are also provided.

A method for producing a retinal pigment epithelial (RPE) cell, including promoting differentiation induction from a pluripotent stem cell into an RPE cell by culturing the pluripotent stem cell in a medium containing an E-cadherin inhibitor is provided by the present invention.

Provided are a pharmaceutical composition or a pharmaceutical composition raw material, which contains supernatant from a culture medium used during culture to induce pluripotent stem cells.

Provided is a method for purifying retinal pigment epithelial cells, with which high-purity retinal pigment epithelial cells can be obtained from a cell population obtained by inducing pluripotent stem cells to differentiate into retinal pigment epithelial cells through a simple and easy operation in a short time. The purification method comprises a step of introducing a cell population containing retinal pigment epithelial cells onto a filter and obtaining a cell population passing through the filter, the cell population being obtained by inducing differentiation of pluripotent stem cells on laminin or fragments thereof.

The present invention relates to a pharmaceutical composition for the prevention or treatment of epilepsy, and an epilepsy therapeutic agent screening method and a composition therefor, and specifically provides an epilepsy therapeutic agent screening method and an epilepsy therapeutic agent screening composition using induced pluripotent stem cells (iPSCs) derived from an epilepsy patient having a genotype comprising an SCN2A gene mutation, and accordingly, a pharmaceutical composition for the prevention or treatment of epilepsy having more excellent efficacy and selectivity than conventional epilepsy therapeutic agents may be screened and provided.

Methods for maintaining aggregate stability and pluripotency of human stem cells are provided using chemically-defined culture media that includes heparin sodium salt and polyethylene glycol. Methods of modulating aggregate size and / or stability using chemically-defined culture media are also provided. The methods can be used with, for example, induced pluripotent stem cells or embryonic stem cells. Culture media and kits are also provided.

The invention provides a preparation method of adult T cells and universal adult CAR-T cells induced and differentiated by pluripotent stem cells, and belongs to the technical field of cell differentiation. By intervening the SP140 gene or SP140 protein, advanced hematopoiesis of pluripotent stem cells can be induced, and hematopoietic precursor cells and adult T cells with T gonadotrophy differentiation potential are obtained. The inducible CAR is knocked into the TRAC site of the pluripotent stem cell at a fixed point, so that endogenous regulation of CAR expression is realized, the in-vivo maintenance and anti-tumor capability of CAR-T is improved, and TCR-mediated graft versus host disease is blocked. The invention also provides a separated CAR-T cell, the CAR-T cell aiming at different antigens can be prepared by editing a seed cell of a pluripotent stem cell once, B2M and CIITA genes are further knocked out, HLA-E is overexpressed, and the immunogenicity of the CAR-T cell and the resistance of a host to the CAR-T cell are reduced.

The present invention relates to NK cells with an improved ability to target and kill cancer cells and use thereof. Specifically, the present invention relates to: iPSC-based NK cells into which a chimeric antigen receptor targeting a specific cancer antigen, CXCR4 and CCR7 genes, which are chemokine receptors, and an IL-15 / IL-15Rα (IL-15RF) gene are introduced; and use thereof for treating cancer. The iPSC-based NK cells according to the present invention can not only directly target a specific cancer antigen by the introduced CAR, but can also activate NK cells and enhance the proliferation thereof by regulating intracellular signaling and tumor microenvironment by the introduced CXCR4 and CCR7 and the introduced IL-15RF. Therefore, the NK cells into which multiple genes are introduced, according to the present invention, can efficiently target and attack cancer cells, and thus can be effectively used for the treatment of cancer diseases.

Provided are a cold storage method and a cold storage liquid that are suitable for non-freezing refrigerated storage of human or animal stem cells such as iPS cells or embryos in a non-frozen state. According to an embodiment, the non-freezing refrigerated storage liquid is: a mixture liquid (HTMα, HTMx2c13), in which MEM-alpha (Minimum Essential Medium Eagle (MEM) Alpha Modification) is mixed with a UW solution (UW_sln; BELZER UW (registered trademark) COLD STORAGE SOLUTION), or a modified UW solution (polymer component being changed to PVA), are mixed in a ratio of about 1 / 1 to 1 / 2; or a storage liquid having a composition equivalent to the mixture liquid, especially in respect of concentrations of potassium ions and sodium ions. And, arousal period(s) of maintaining a temperature of 30° C. to 37° C. is inserted at each of two to five days, into a non-freezing refrigerated storage period, which is made at 2° C. to 8° C. for 2 to 10 days or 4 to 20 days.